Optinose Appoints Terry Kohler as Chief Financial Officer

Core Insights - Optinose has appointed Terry Kohler as Chief Financial Officer, bringing over 20 years of experience in biotech finance [1][2][3] - Kohler's previous role was at Verrica Pharmaceuticals, where he supported the launch of a topical treatment and R&D investments [2] - The CEO expressed confidence in Kohler's ability to guide the financial strategy for XHANCE, a treatment for chronic rhinosinusitis [3] Company Overview - Optinose is a specialty pharmaceutical company focused on patients treated by ENT and allergy specialists [5] - The company is working to maximize the value of XHANCE, which is approved for chronic rhinosinusitis [3][6] Product Information - XHANCE is a nasal spray designed to deliver a topical steroid to the nasal cavity, approved for chronic rhinosinusitis with and without nasal polyps [6] - The product utilizes the Exhalation Delivery System™ to enhance drug delivery [6] Compensation Details - Kohler received a non-qualified stock option to purchase 675,000 shares at $0.71 per share and 150,000 restricted stock units as part of his inducement to join the company [4] - The stock options and restricted stock units will vest over four years, contingent on Kohler's continuous service [4]